Comparative Pharmacology
Head-to-head clinical analysis: DEXTENZA versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTENZA versus STERI STAT.
DEXTENZA vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a corticosteroid with glucocorticoid activity that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune cell migration and activation.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
Insert 0.4 mg intracanalicularly (into the lacrimal punctum) as a single dose; releases dexamethasone over 30 days.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
The terminal elimination half-life of dexamethasone from plasma after systemic absorption is approximately 3-4 hours. However, Dextenza provides sustained local delivery to the ocular surface; the insert releases dexamethasone over 30 days, with therapeutic levels maintained throughout.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Dextenza (dexamethasone ophthalmic insert) is administered intracanalicularly; systemic absorption is minimal. Following release into the tear film, the drug is primarily eliminated via nasolacrimal drainage and subsequent gastrointestinal absorption with hepatic metabolism. Renal excretion accounts for <5% of the dose as unchanged drug; biliary/fecal elimination is negligible.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid